Pathology oncology research : POR最新文献

{"title":"KIAA1199 Correlates With Tumor Microenvironment and Immune Infiltration in Lung Adenocarcinoma as a Potential Prognostic Biomarker.","authors":"Xiaoju Shen,&nbsp;Xiaocheng Mo,&nbsp;Weidan Tan,&nbsp;Xiaoxiang Mo,&nbsp;Li Li,&nbsp;Fei Yu,&nbsp;Jingchuan He,&nbsp;Zhihua Deng,&nbsp;Shangping Xing,&nbsp;Zhiquan Chen,&nbsp;Jie Yang","doi":"10.3389/pore.2022.1610754","DOIUrl":"https://doi.org/10.3389/pore.2022.1610754","url":null,"abstract":"<p><p><b>Background:</b> KIAA1199 has been considered a key regulator of carcinogenesis. However, the relationship between KIAA1199 and immune infiltrates, as well as its prognostic value in lung adenocarcinoma (LUAD) remains unclear. <b>Methods:</b> The expression of KIAA1199 and its influence on tumor prognosis were analyzed using a series of databases, comprising TIMER, GEPIA, UALCAN, LCE, Prognoscan and Kaplan-Meier Plotter. Further, immunohistochemistry (IHC), western blot (WB) and receiver operating characteristic (ROC) curve analyses were performed to verify our findings. The cBioPortal was used to investigate the genomic alterations of KIAA1199. Prediction of candidate microRNA (miRNAs) and transcription factor (TF) targeting KIAA1199, as well as GO and KEGG analyses, were performed based on LinkedOmics. TIMER and TISIDB databases were used to explore the relationship between KIAA1199 and tumor immune infiltration. <b>Results:</b> High expression of KIAA1199 was identified in LUAD and Lung squamous cell carcinoma (LUSC) patients. High expression of KIAA1199 indicated a worse prognosis in LUAD patients. The results of IHC and WB analyses showed that the expression level of KIAA1199 in tumor tissues was higher than that in adjacent tissues. GO and KEGG analyses indicated KIAA1199 was mainly involved in extracellular matrix (ECM)-receptor interaction and extracellular matrix structure constituent. KIAA1199 was positively correlated with infiltrating levels of CD4⁺ T cells, macrophages, neutrophil cells, dendritic cells, and showed positive relationship with immune marker subsets expression of a variety of immunosuppressive cells. <b>Conclusion:</b> High expression of KIAA1199 predicts a poor prognosis of LUAD patients. KIAA1199 might exert its carcinogenic role in the tumor microenvironment <i>via</i> participating in the extracellular matrix formation and regulating the infiltration of immune cells in LUAD. The results indicate that KIAA1199 might be a novel biomarker for evaluating prognosis and immune cell infiltration in LUAD.</p>","PeriodicalId":411887,"journal":{"name":"Pathology oncology research : POR","volume":" ","pages":"1610754"},"PeriodicalIF":2.8,"publicationDate":"2022-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40702381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer.","authors":"Jianmin Zeng,&nbsp;Man Li,&nbsp;Kefan Dai,&nbsp;Bingyu Zuo,&nbsp;Jianhui Guo,&nbsp;Lu Zang","doi":"10.3389/pore.2022.1610643","DOIUrl":"https://doi.org/10.3389/pore.2022.1610643","url":null,"abstract":"<p><p><b>Background:</b> The aim of this study was to construct a glycolysis-related long noncoding RNA (lncRNA) signature to predict the prognosis of patients with gastric cancer (GC). <b>Methods:</b> Glycolysis-related genes were obtained from the Molecular Signatures Database (MSigDB), lncRNA expression profiles and clinical data of GC patients were obtained from The Cancer Genome Atlas database (TCGA). Furthermore, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator (LASSO) and multivariate Cox regression analysis were used to construct prognostic glycolysis-related lncRNA signature. The specificity and sensitivity of the signature was verified by receiver operating characteristic (ROC) curves. We constructed a nomogram to predict the 1-year, 3-year, and 5-year survival rates of GC patients. Besides, the relationship between immune infiltration and the risk score was analyzed in the high and low risk groups. Multi Experiment Matrix (MEM) was used to analyze glycolysis-related lncRNA target genes. R \"limma\" package was used to analyze the mRNA expression levels of the glycolysis-related lncRNA target genes in TCGA. Gene set enrichment analysis (GSEA) was employed to further explore the biological pathways in the high-risk group and the glycolysis-related lncRNA target gene. <b>Results:</b> A prognostic signature was conducted based on nine glycolysis-related lncRNAs, which are AL391152.1, AL590705.3, RHOXF1-AS1, CFAP61-AS1, LINC00412, AC005165.1, AC110995.1, AL355574.1 and SCAT1. The area under the ROC curve (AUC) values at 1-year, 3-year, and 5-year were 0.765, 0.828 and 0.707 in the training set, and 0.669, 740 and 0.807 in the testing set, respectively. In addition, the nomogram could efficaciously predict the 1-year, 3-year, and 5-year survival rates of the GC patients. Then, we discovered that GC patients with high-risk scores were more likely to respond to immunotherapy. GSEA revealed that the signature was mainly associated with the calcium signaling pathway, extracellular matrix (ECM) receptor interaction, and focal adhesion in high-risk group, also indicated that SBSPON is related to aminoacyl-tRNA biosynthesis, citrate cycle, fructose and mannose metabolism, pentose phosphate pathway and pyrimidine metabolism. <b>Conclusion:</b> Our study shows that the signature can predict the prognosis of GC and may provide new insights into immunotherapeutic strategies.</p>","PeriodicalId":411887,"journal":{"name":"Pathology oncology research : POR","volume":" ","pages":"1610643"},"PeriodicalIF":2.8,"publicationDate":"2022-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40702380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anterior Gradient 2 is a Significant Prognostic Biomarker in Bone Metastasis of Breast Cancer.","authors":"Jin-Jin Li,&nbsp;Shuai Wang,&nbsp;Zhong-Ning Guan,&nbsp;Jin-Xi Zhang,&nbsp;Ri-Xin Zhan,&nbsp;Jian-Long Zhu","doi":"10.3389/pore.2022.1610538","DOIUrl":"https://doi.org/10.3389/pore.2022.1610538","url":null,"abstract":"<p><p><b>Background:</b> The study aimed to detect DEGs associated with BRCA bone metastasis, filter prognosis biomarkers, and explore possible pathways. <b>Methods:</b> GSE175692 dataset was used to detect DEGs between BRCA bone metastatic cases and non-bone metastatic cases, followed by the construction of a PPI network among DEGs. The main module among the PPI network was then determined and pathway analysis on genes within the module was performed. Through performing Cox regression, Kaplan-Meier, nomogram, and ROC curve analyses using GSE175692 and GSE124647 datasets at the same time, the most significant prognostic biomarker was gradually filtered. Finally, important pathways associated with prognostic biomarkers were explored by GSEA analysis. <b>Results:</b> The 74 DEGs were detected between bone metastasis and non-bone metastasis groups. A total of 15 nodes were included in the main module among the whole PPI network and they mainly correlated with the IL-17 signaling pathway. We then performed Cox analysis on 15 genes using two datasets and only enrolled the genes with <i>p</i> < 0.05 in Cox analysis into the further analyses. Kaplan-Meier analyses using two datasets showed that the common biomarker AGR2 expression was related to the survival time of BRCA metastatic cases. Further, the nomogram determined the greatest contribution of AGR2 on the survival probability and the ROC curve revealed its optimal prognostic performance. More importantly, high expression of AGR2 prolonged the survival time of BRCA bone metastatic patients. These results all suggested the importance of AGR2 in metastatic BRCA. Finally, we performed the GSEA analysis and found that AGR2 was negatively related to IL-17 and NF-kβ signaling pathways. <b>Conclusion:</b> AGR2 was finally determined as the most important prognostic biomarker in BRCA bone metastasis, and it may play a vital role in cancer progression by regulating IL-17 and NF-kB signaling pathways.</p>","PeriodicalId":411887,"journal":{"name":"Pathology oncology research : POR","volume":" ","pages":"1610538"},"PeriodicalIF":2.8,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40502464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients.","authors":"Qi Huo,&nbsp;Junjie Hu,&nbsp;Binfen Hou,&nbsp;Mei Zhao,&nbsp;Xue Han,&nbsp;Yulin Du,&nbsp;Yao Li","doi":"10.3389/pore.2022.1610396","DOIUrl":"https://doi.org/10.3389/pore.2022.1610396","url":null,"abstract":"Background: Typically, liver cancer patients are diagnosed at an advanced stage and have a poor prognosis. N-recognin 5 (UBR5), a component of the ubiquitin protein ligase E3, is involved in the genesis and progression of several types of cancer. As of yet, it is unknown what the exact biological function of UBR5 is in liver cancer. Methods: A Kaplan-Meier survival curve (OS) was used to examine the effect of UBR5 expression on overall survival based on the TCGA database. To determine the molecular functions of UBR5 in liver cancer, we used the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. A protein-protein interaction (PPI) network was established for the screening of UBR5-related proteins in liver cancer. Western blot analysis was used to determine the expression levels of UBR5 and YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta), and in order to detect cell proliferation, an MTT assay was used. Results: The expression of UBR5 in liver cancer patient samples is significantly higher than in adjacent normal tissues. A high level of UBR5 expression was associated with older patients, a higher tumor grade, lymph node metastasis, and poor survival. We discovered YWHAZ with high connectivity, and UBR5 expression correlated positively with YWHAZ expression (r = 0.83, p < 0.05). Furthermore, we found that elevated UBR5 levels directly correlated with YWHAZ overexpression, and that UBR5 promoted cell proliferation by affecting YWHAZ expression. Additionally, the TCGA databases confirmed that patients with liver cancer who expressed higher levels of YWHAZ had poorer outcomes. Conclusion: This suggests that UBR5 associated with YWHAZ may influence prognosis in patients with liver cancer, and that UBR5 may be a candidate treatment target for liver cancer. Therefore, UBR5 associated with YWHAZ may influence prognosis in patients with liver cancer, and UBR5 could serve as a potential target for liver cancer treatment.","PeriodicalId":411887,"journal":{"name":"Pathology oncology research : POR","volume":" ","pages":"1610396"},"PeriodicalIF":2.8,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40469626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Extracellular Vesicles-Derived miR-99a-5p: A Potential Biomarker to Predict Early Head and Neck Squamous Cell Carcinoma.","authors":"Qiang Huang,&nbsp;Yu-Jie Shen,&nbsp;Chi-Yao Hsueh,&nbsp;Yi-Fan Zhang,&nbsp;Xiao-Hui Yuan,&nbsp;Yu-Juan Zhou,&nbsp;Jiao-Yu Li,&nbsp;Lan Lin,&nbsp;Chun-Ping Wu,&nbsp;Chun-Yan Hu","doi":"10.3389/pore.2022.1610699","DOIUrl":"https://doi.org/10.3389/pore.2022.1610699","url":null,"abstract":"<p><p><b>Purpose:</b> This study aimed to investigate the applicability of plasma extracellular vesicles (EVs) miR-99a-5p as a potential head and neck squamous cell carcinoma (HNSCC) diagnostic biomarker. <b>Methods:</b> The miRNA expression of HNSCC tissue and plasma EVs were profiled by small RNA sequencing. qRT-PCR was performed to detect miR-99a-5p expression in HNSCC (<i>n</i> = 93) and benign disease (<i>n</i> = 39) plasma EVs and formalin-fixed and paraffin-embedded (FFPE) tissue (<i>n</i> = 110). We constructed receiver-operating characteristic curves to investigate the diagnostic efficiency of plasma EVs miR-99a-5p. <b>Results:</b> Tumor tissue exhibited lower miR-99a-5p than para-tumor tissue. Patients with high miR-99a-5p expression exhibited significantly more p16 positive status. In contrast, HNSCC plasma EVs harbored more miR-99a-5p than the benign disease group. Plasma EVs miR-99a-5p distinguished HNSCC with area under the curve (AUC) of 0.7494 (95% CI: 0.6692-0.8296; <i>p</i> < 0.0001), with 61.54% sensitivity and 75.27% specificity, respectively. Furthermore, plasma EVs miR-99a-5p also distinguished early HNSCC with AUC of 0.7394 (95% CI: 0.6284-0.8504; <i>p</i> = 0.0002), with 79.07% sensitivity and 61.54% specificity, respectively. <b>Conclusion:</b> Plasma EVs miR-99a-5p is a potential biomarker for predicting early HNSCC.</p>","PeriodicalId":411887,"journal":{"name":"Pathology oncology research : POR","volume":" ","pages":"1610699"},"PeriodicalIF":2.8,"publicationDate":"2022-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40443754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved Accuracy of Lymph Node Staging and Long-Term Survival Benefit in Colorectal Cancer With <i>Ex Vivo</i> Arterial Methylene Blue Infiltration.","authors":"Nóra Suszták,&nbsp;István Besznyák,&nbsp;Kálmán Almási,&nbsp;Attila Bursics,&nbsp;Dóra Kelemen,&nbsp;David W Borowski,&nbsp;Balázs Bánky","doi":"10.3389/pore.2022.1610742","DOIUrl":"https://doi.org/10.3389/pore.2022.1610742","url":null,"abstract":"<p><p><b>Introduction:</b> <i>Ex vivo</i> methylene blue (MB) injection into the main supplying arteries of the colorectal specimen after surgical removal is an uncomplicated technique to support lymph node harvest during pathological evaluation. The primary aim of this randomized, interventional, bicentric trial was to evaluate the impact of MB injection on lymph node yield, with secondary aims assessing the accuracy of lymph node staging and the effect on 5-year overall survival for patients undergoing resection of colorectal cancer. <b>Methods:</b> In the study period between December 2013 and August 2015, 200 colorectal resections were performed at two independent onco-surgery centers of Hungary. Following surgical resection, each specimen was randomly assigned either to the control (standard pathological work-up) or to the MB staining group before formaldehyde fixation. Patient-level surgical and clinical data were retrieved from routinely collected clinical datasets. Survival status data were obtained from the National Health Insurance Fund of Hungary. <b>Results:</b> A total of 162 specimens, 82 in the control and 80 in the MB groups, were included for analysis. Baseline characteristics were equally distributed among study groups, except for specimen length. Both the median of total number of lymph nodes retrieved (control 11 ± 8 [0-33] nodes vs. MB 14 ± 6 [0-42] nodes; <i>p</i> < 0.01), and the ratio of cases with at least 12 removed lymph nodes (36/82, 43.9% vs. 53/80, 66.3%; <i>p</i> < 0.01) were higher in the MB group. The rate of accurate lymph node staging was non-significantly improved. As for rectal cancer, nodal staging accuracy (16/31, 51.6% vs. 23/30, 76.7%; <i>p</i> = 0.04) and the proportion with minimum 12 lymph node retrieval (7/31, 22.6%, vs. 18/30, 60%; <i>p</i> < 0.01) was improved by MB injection. In Mantel-Cox regression, a statistically significant survival benefit with methylene blue injection at 5 years post-surgery was proven (51.2% vs. 68.8%; <i>p</i> = 0.04). <b>Conclusion:</b> In our experience, postoperative <i>ex vivo</i> arterial methylene blue injection appears to be an uncomplicated technique, improving lymph node yield and decreasing the chance of insufficient nodal staging. The technique might also associate with a 5-year overall survival benefit.</p>","PeriodicalId":411887,"journal":{"name":"Pathology oncology research : POR","volume":" ","pages":"1610742"},"PeriodicalIF":2.8,"publicationDate":"2022-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40443752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Molecular Analyses of an SLC Family-Based Model in Stomach Adenocarcinoma.","authors":"Tao Yu,&nbsp;Shao-Kun Yu,&nbsp;Kai-Hua Lu","doi":"10.3389/pore.2022.1610610","DOIUrl":"https://doi.org/10.3389/pore.2022.1610610","url":null,"abstract":"<p><p><b>Background:</b> Solute carrier (SLC) family members are crucial in transporting amino acids across membranes. Amino acids are indispensable for both cancer and immune cells. However, the clinical significance of amino acid transporting SLC members in stomach adenocarcinoma (STAD) remains unclear. This study aimed to develop an SLC family-based model to predict the prognosis and the response of STAD patients to immunotherapy. <b>Methods:</b> A total of 1239 tumor cases were obtained from online databases. The training set (<i>n</i> = 371) consisted of RNA sequencing profiles obtained from The Cancer Genome Atlas (TCGA), while those from Gene Expression Omnibus (GEO) were used as the test set. Subsequently, the clinical characteristics and immune profiles were investigated, and potential immunotherapy response prediction values of the model were assessed. <b>Results:</b> Based on the TCGA cohort, an SLC family-based model was developed using multivariate Cox analysis. All tumor cases were stratified into high- and low-risk groups considering the SLC model. High-risk patients had a worse overall survival (OS) than low-risk patients, consistent with the results of GEO cohorts. Comprehensive analyses revealed that the high-risk group was correlated with aggressiveness-related pathways, whereas the low-risk group had better T helper cell infiltration and stronger immunotherapy response. Compared to the high-risk group, the low-risk group presented increased PD-L1 and tumor mutation burden. <b>Conclusion:</b> This SLC family-based model has the potential to predict the prognosis and immunotherapy outcomes of STAD patients. The survival of patients in the low-risk group was greatly prolonged, and the patients may benefit more from immunotherapy.</p>","PeriodicalId":411887,"journal":{"name":"Pathology oncology research : POR","volume":" ","pages":"1610610"},"PeriodicalIF":2.8,"publicationDate":"2022-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40439085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary Large Cell Neuroendocrine Carcinoma.","authors":"Lan Yang,&nbsp;Ying Fan,&nbsp;Hongyang Lu","doi":"10.3389/pore.2022.1610730","DOIUrl":"https://doi.org/10.3389/pore.2022.1610730","url":null,"abstract":"<p><p>Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare subtype of malignant pulmonary tumor. The incidence rate of LCNEC was reported to be 0.3%-3% in lung cancers. Although LCNEC is classified as non-small cell lung cancer (NSCLC), it is more aggressive and malignant than other NSCLC, and its biological behavior is similar to that of small cell lung cancer (SCLC). Most of the LCNEC patients are elderly smoking male and the clinical manifestations are not specific. The imaging manifestations of the tumors are often located in the periphery and the upper lobes, and the enlargement of mediastinal or hilar lymph nodes is common. The diagnosis is mainly based on pathology by the histological features and immunohistochemistry (IHC). Specific neuroendocrine markers such as chromogranin A (CgA), synaptophysin (Syn) and CD56 are usually diffusely positive in LCNEC, and found that insulinoma-associated protein (INSM1) and high rate of Ki-67 are helpful for diagnosis. More differential diagnoses also increase the difficulty of correctly diagnosing LCNEC. The rise of LCNEC molecular typing in recent years may be helpful for diagnosis and subsequent treatment. This review focuses on the epidemiological features, imaging studies, pathology, diagnosis, treatment, and prognosis of LCNEC.</p>","PeriodicalId":411887,"journal":{"name":"Pathology oncology research : POR","volume":" ","pages":"1610730"},"PeriodicalIF":2.8,"publicationDate":"2022-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40441276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: High Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer.","authors":"Nándor Polk,&nbsp;Barna Budai,&nbsp;Erika Hitre,&nbsp;Attila Patócs,&nbsp;Tamás Mersich","doi":"10.3389/pore.2022.1610658","DOIUrl":"https://doi.org/10.3389/pore.2022.1610658","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/pore.2022.1610315.].</p>","PeriodicalId":411887,"journal":{"name":"Pathology oncology research : POR","volume":" ","pages":"1610658"},"PeriodicalIF":2.8,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40655547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overexpression of Dehydrogenase/Reductase 9 Predicts Poor Response to Concurrent Chemoradiotherapy and Poor Prognosis in Rectal Cancer Patients.","authors":"Tzu-Ju Chen,&nbsp;Bei-Hao Hsu,&nbsp;Sung-Wei Lee,&nbsp;Ching-Chieh Yang,&nbsp;Yu-Feng Tian,&nbsp;Yu-Hsuan Kuo,&nbsp;Wan-Shan Li,&nbsp;Hsin-Hwa Tsai,&nbsp;Li-Ching Wu,&nbsp;Cheng-Fa Yeh,&nbsp;Chia-Lin Chou,&nbsp;Hong-Yue Lai","doi":"10.3389/pore.2022.1610537","DOIUrl":"https://doi.org/10.3389/pore.2022.1610537","url":null,"abstract":"<p><p><b>Objective:</b> To reduce the risk of locoregional recurrence, the addition of neoadjuvant concurrent chemoradiotherapy (CCRT) is recommended before surgical management for rectal cancer patients. However, despite identical tumor histology, individual patient response to neoadjuvant CCRT varies greatly. Accordingly, a comprehensive molecular characterization that is used to predict CCRT efficacy is instantly needed. <b>Methods:</b> Pearson's chi-squared test was utilized to correlate dehydrogenase/reductase 9 (DHRS9) expression with clinicopathological features. Survival curves were created applying the Kaplan-Meier method, and the log-rank test was conducted to compare prognostic utility between high and low DHRS9 expression groups. Multivariate Cox proportional hazards regression analysis was applied to identify independent prognostic biomarkers based on variables with prognostic utility at the univariate level. <b>Results:</b> Utilizing a public transcriptome dataset, we identified that the <i>DHRS9</i> gene is the most considerably upregulated gene related to epithelial cell differentiation (GO: 0030855) among rectal cancer patients with CCRT resistance. Employing immunohistochemical staining, we also demonstrated that high DHRS9 immunoexpression is considerably associated with an aggressive clinical course and CCRT resistance in our rectal cancer cohort. Among all variables with prognostic utility at the univariate level, only high DHRS9 immunoexpression was independently unfavorably prognostic of all three endpoints (all <i>p</i> ≤ 0.048) in the multivariate analysis. In addition, applying bioinformatic analysis, we also linked <i>DHRS9</i> with unrevealed functions, such as keratan sulfate and mucin synthesis which may be implicated in CCRT resistance. <b>Conclusion:</b> Altogether, <i>DHRS9</i> expression may serve as a helpful predictive and prognostic biomarker and assist decision-making for rectal cancer patients who underwent neoadjuvant CCRT.</p>","PeriodicalId":411887,"journal":{"name":"Pathology oncology research : POR","volume":" ","pages":"1610537"},"PeriodicalIF":2.8,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40655545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}